QualityStocks.net News – CytRx Corp. (CYTR) to Present Positive, Stroke-Related Discovery at Sixth International Workshop in Thailand

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

We would like to highlight CytRx Corporation (NASDAQ: CYTR). The company is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone amplification” technology. In September 2006, CytRx announced that arimoclomol was shown to be safe and well-tolerated at all three doses tested in its Phase IIa clinical trial in patients with ALS. The Company's Phase IIb clinical trial with arimoclomol for ALS was placed on clinical hold in January 2008, and the Company has announced its intention to work diligently with the FDA to reach resolution.

In the Company’s news yesterday,

CytRx Corp. announced Shi Chung Ng, Ph.D., the biopharmaceutical company’s senior vice president of research and development, will present results of its recent studies at the Sixth International Workshop on the Molecular Biology of Stress Responses at the Chulabhorn Research Institute in Bangkok, Thailand.

CytRx is engaged in the development and commercialization of human therapeutics through animal testing. It recently conducted studies surrounding animal stroke and the company’s lead molecular chaperone amplification drug candidate arimoclomol, which Dr. Ng will present at the upcoming workshop.

In the press release, Dr. Ng said most previous-generation stroke drug candidates were designed to prevent brain cells from dying in the acute stage of a stroke by re-establishing blood flow or protecting cells from the lack of oxygen. The studies of arimoclomol differ, showing that the brain cells aren’t prevented from dying, but are repaired.

“The results of our studies presented at this meeting suggest that arimoclomol improves recovery from stroke not by decreasing the number of brain cells that die, but by repairing the brain cells that survived but that were otherwise too injured to function normally,” Dr. Ng stated. “This may explain why arimoclomol demonstrated statistically significant improvement in recovery even when the drug was administered well after the event. We are pleased to share the results of our study at this important workshop that attracts scientific thought-leaders from around the world.”

In the presentation, Dr. Ng will discuss the positive effects arimoclomol had on rats immediately after a stroke was induced. Rats treated with the drug recovered more quickly, and the recovery was not contingent on the time the drug was orally administered. The studies are aimed at reducing the damaging effects of strokes in humans.

CytRx’s Chief Scientific Officer Jack Barber, Ph.D, stated, “The results from these rat studies with arimoclomol in stroke recovery are sufficiently compelling that we are working toward entering a Phase II clinical trial in stroke recovery in the second half of this year, subject to U.S. Food and Drug Administration (FDA) clearance.”

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net